REG - AstraZeneca PLC - Block listing Interim Review <Origin Href="QuoteRef">AZN.L</Origin>

AstraZenecaAnnouncement

01/12/2016 16:00

RNS Number : 7410Q
AstraZeneca PLC
01 December 2016
1 December 2016 16:00
BLOCK LISTING SIX MONTHLY RETURN
Information provided on this form must be typed or printed electronically and provided to an ris.
Date: 1 DECEMBER 2016
Name of applicant:
ASTRAZENECA PLC
Name of scheme:
ASTRAZENECA SHARE OPTION PLAN; ASTRAZENECA SAVINGS-RELATED SHARE OPTION PLAN; ASTRAZENECA ALL-EMPLOYEE SHARE PLAN; ASTRAZENECA PLC 2012 SAVINGS-RELATED SHARE OPTION SCHEME
Period of return:
From:
31 MAY 2016
To:
30 NOVEMBER 2016
Balance of unallotted securities under scheme(s) from previous return:
4,065,743
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for):
0
Less: Number of securities issued/allotted under scheme(s) during period (see LR3.5.7G):
478,408
Equals: Balance under scheme(s) not yet issued/allotted at end of period:
3,587,335
Name of contact:
MARTIN BENNETT
Telephone number of contact:
07825 530066
About AstraZeneca
AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three main therapy areas - Oncology, Cardiovascular & Metabolic Diseases and Respiratory. The Company also is selectively active in the areas of autoimmunity, neuroscience and infection. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information, please visit www.astrazeneca.comand follow us on Twitter @AstraZeneca.
Media Enquiries
Neil Burrows
UK/Global
+44 203 749 5637
Vanessa Rhodes
UK/Global
+44 203 749 5736
Karen Birmingham
UK/Global
+44 203 749 5634
Rob Skelding
UK/Global
+44 203 749 5821
Jacob Lund
Sweden
+46 8553260 20
Michele Meixell
US
+1 302 885 2677



Investor Relations


Thomas Kudsk Larsen
+44 203 749 5712
Craig Marks
Finance, Fixed Income, M&A
+44 7881 615 764
Henry Wheeler
Oncology
+44 203 749 5797
Mitchell Chan
Oncology
+1 240 477 3771
Lindsey Trickett
Cardiovascular & Metabolic Diseases
+1 240 543 7970
Nick Stone
Respiratory
+44 203 749 5716
Christer Gruvris
Autoimmunity, neuroscience & infection
+44 203 749 5711
US toll free

+1 866 381 7277
Adrian Kemp
Company Secretary, AstraZeneca PLC
-ENDS-

This information is provided by RNS
The company news service from the London Stock Exchange
  END
BLRFSFFIFFMSEFE